Precision oncology: current and future platforms for treatment selection.

Abstract excerpt

Genomic profiling of hundreds of cancer-associated genes is now a component of routine cancer care. DNA sequencing can identify mutations, mutational signatures, and structural alterations predictive of therapy response and assess for heritable cancer risk, but it has been less useful for identifying predictive biomarkers of sensitivity to cytotoxic chemotherapies, antibody drug conjugates, and immunotherapies....

Topics

Join the communities discussing this publication.

• Molecular Targeted Therapy
• Biomarkers, Tumor
• Genomics
• High-Throughput Nucleotide Sequencing
• Immunotherapy